id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-311216-mfqlv3nh	Buckley, Leo F.	Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2	2020-04-13		.txt	text/plain	2126	124	38	Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin-converting enzyme 2 (ACE2). We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology, as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin–angiotensin–aldosterone system inhibitor therapy. [2] [3] [4] [5] [6] [7] [8] SARS-CoV-2 infects host cells by binding to human angiotensin-converting enzyme-2 (ACE2), [9] [10] [11] a membranebound enzyme expressed in the lungs, heart, and kidneys (among many other organs). 15 It has been proposed that renin-angiotensin-aldosterone system (RAAS) inhibitors predispose to SARS-CoV-19 infection and worsen outcomes after COVID-19 by upregulating ACE2 expression. Epidemiologic studies should be performed to estimate the association of RAAS inhibitor use to risk of COVID-19 in patients with hypertension, heart failure or chronic kidney disease. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients	./cache/cord-311216-mfqlv3nh.txt	./txt/cord-311216-mfqlv3nh.txt